Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Chinese Patent Office
Chubb
UBS
Merck
Cipla
Fuji
Baxter

Generated: May 25, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,424,286

« Back to Dashboard

Summary for Patent: 5,424,286
Title: Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
Abstract:This invention encompasses pharmaceutical compositions containing exendin-3 or exendin-4, fragments thereof, or any combination thereof, and methods for the treatment of diabetes mellitus and the prevention of hyperglycemia.
Inventor(s): Eng; John (Bronx, NY)
Assignee:
Application Number:08/066,480
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,424,286
Patent Claims: 1. A polypeptide having the amino acid sequence:

HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG P[SEQ ID No:3].

2. A polypeptide having the amino acid sequence:

HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG Y[SEQ ID No:4].

3. A pharmaceutical composition which comprises an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence of claim 1 in a suitable carrier, which will stimulate the secretion of insulin in vivo.

4. A pharmaceutical composition which comprises an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified form natural sources, having the amino acid sequence of claim 2 in a suitable carrier, which will stimulate the secretion of insulin in vivo.

5. A method of stimulating insulin release in a mammal comprising administering an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence:

wherein the resulting insulinotropic effect is greater than that attainable by administration of GLP-1.

6. A method of stimulating insulin release in a mammal comprising administering an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence:

wherein the resulting insulinotropic effect is greater than that attainable by administration of GLP-1.

7. A method of inhibiting insulin release in a mammal comprising administering an effective amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence:

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Colorcon
Accenture
Cerilliant
QuintilesIMS
Healthtrust
Argus Health
Cipla
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.